David R. Wise, MD, PhDD
2018 may be the year that checkpoint inhibition breaks through in the treatment landscape of prostate cancer, according to David R. Wise, MD, PhD.
on Genitourinary Cancers, Wise, an assistant professor at NYU Langone’s Perlmutter Cancer Center, discussed the promise for immunotherapy and other emerging approaches in the field of prostate cancer.
OncLive: Can you please provide an overview of your presentation?
: I gave an overview of some of the newer approaches for prostate cancer treatment. I covered some of the recent advancements in novel androgen receptor (AR)-directed therapies for use in advanced prostate cancer, with the theme of "earlier is better.” Using our more effective and very well-tolerated therapeutics in patients who present with newly diagnosed metastatic non–castration-resistant prostate cancer has dramatically improved outcomes, and our patients are already benefitting from them. We took more of a granular look at those studies and analyzed some of the limitations, but also some of the nice results and how to apply them in the current clinical setting.
... to read the full story